Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard
Executive Summary
Actelion spin-off Idorsia is becoming the largest shareholder in Santhera after deciding its fellow Switzerland-based group is best placed to advance its optioned DMD candidate vamorolone.